Open Nav

NeuroDiagnostics LLC

Series C Round - $2.5-$5.0 million

  • Date:Wednesday, October 17
  • Time:9:30 AM - 9:45 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:NeuroDiagnostics (NDX) has developed a groundbreaking test for diagnosing Alzheimer's Disease (AD) – it is the only extremely accurate test to identify and differentiate it from other sources of dementia – called Discern™ o The test is non-invasive (2-3 millimeter skin punch biopsy already commonly performed by nurses everyday) and can distinguish between AD, non-AD and healthy patients o The test is the result of over 15 years of research at the Blanchette Rockefeller Neurosciences Institute (BRNI), now part of West Virginia University, and confirmed by subsequent brain autopsies conducted at Johns Hopkins University o The NDX test has a sensitivity (accuracy) of 95%+ and specificity (meaning it does not have false positives) of 95%+ • NDX achieved “Breakthrough Status” with the FDA this year o In August 2018, NDX submitted clinical developmental and validation data that supports the intended use of its 3 independent non-invasive Alzheimer’s Disease (AD) Biomarkers.
  • Company Website:neurodiagnosticsllc.com (in development)
  • Company HQ City:Rockville
  • Company HQ Country:United States
  • Company HQ State:Maryland                  
  • CEO/Top Company Official:Paul Tanico, CEO
  • Year Founded:2016
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :Discern Alzheimer's Test
  • Development Phase of Primary Product:Other/Not Applicable
  • Additional Information/Comments:FDA recently granted "Breakthrough Status" for the Discern Alzhiemer's Test; NeuroDiagnostics has been operating under the "radar screen" to build the foundation for the company. Hence, the website, etc. is under development. This will be the "first public presentation" of the company.
  • Previous and Current Investors:CastleRock Management, Atalanta Sosnoff Capital, Private Angels
  • Size of Last Investment Round:$1.5 million
  • Total Amount Raised to Date, In All Rounds:$2.4 million
Speakers
Paul Tanico
NeuroDiagnostics (NDX)
Back